CervoMed Inc. - 8-K Filing

CervoMed's Phase 2a trial results for neflamapimod in nfvPPA accepted as a late-breaking oral presentation at ISFTD Annual Meeting (Items: 7.01 of this Current Report on Form 8-K)

SEC EDGAR ·

Tickers: $CRVO

Read the full article at SEC EDGAR

More Regulatory news